Understanding Chronic GVHD from Different Angles

Biology of Blood and Marrow Transplantation

Volumn 18, Issue 1 SUPPL., 2012, Pages

  Blazar, Bruce ^a   White, Eric S ^b   Couriel, Daniel ^b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CD86 ANTIGEN; CYCLOPHOSPHAMIDE; FIBRONECTIN; RITUXIMAB; TOLL LIKE RECEPTOR 9; TRANSFORMING GROWTH FACTOR BETA;

ACUTE GRAFT VERSUS HOST DISEASE; ARTICLE; B LYMPHOCYTE; BRONCHIOLITIS OBLITERANS; CD4+ T LYMPHOCYTE; CHRONIC GRAFT VERSUS HOST DISEASE; DIABETIC NEPHROPATHY; DRUG MEGADOSE; EPITHELIAL MESENCHYMAL TRANSITION; FOLLOW UP; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LUNG DISEASE; NEUTROPHIL; NONHUMAN; RESPIRATORY DISTRESS SYNDROME; SCLERODERMA; SCORING SYSTEM; SKIN FIBROSIS; T LYMPHOCYTE;

ANIMALS; B-LYMPHOCYTES; CHRONIC DISEASE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MICE; T-LYMPHOCYTES; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 84855363639     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2011.10.025     Document Type: Article

References (29)

1. Filipovich A.H., Weisdorf D., Pavletic S., et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005, 11:945-956.
2. Baird K., Cooke K., Schultz K.R. Chronic graft-versus-host disease (GVHD) in children. Pediatr Clin North Am 2010, 57:297-322.
3. Kapur R., Ebeling S., Hagenbeek A. B-cell involvement in chronic graft-versus-host disease. Haematologica 2008, 93:1702-1711.
4. Fujii H., Cuvelier G., She K., et al. Biomarkers in newly diagnosed pediatric-extensive chronic graft-versus-host disease: a report from the Children's Oncology Group. Blood 2008, 111:3276-3285.
5. Sarantopoulos S., Stevenson K.E., Kim H.T., et al. High levels of B-cell activating factor in patients with active chronic graft-versus-host disease. Clin Cancer Res 2007, 13:6107-6114.
6. Sarantopoulos S., Stevenson K.E., Kim H.T., et al. Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease. Blood 2009, 113:3865-3874.
7. She K., Gilman A.L., Aslanian S., et al. Altered Toll-like receptor 9 responses in circulating B cells at the onset of extensive chronic graft-versus-host disease. Biol Blood Marrow Transplant 2007, 13:386-397.
8. Zhang C., Todorov I., Zhang Z., et al. Donor CD4+ T and B cells in transplants induce chronic graft-versus-host disease with autoimmune manifestations. Blood 2006, 107:2993-3001.
9. Chu Y.W., Gress R.E. Murine models of chronic graft-versus-host disease: insights and unresolved issues. Biol Blood Marrow Transplant 2008, 14:365-378.
10. Panoskaltsis-Mortari A., Tram K.V., Price A.P., Wendt C.H., Blazar B.R. A new murine model for bronchiolitis obliterans post-bone marrow transplant. Am J Respir Crit Care Med 2007, 176:713-723.
11. Dudek A.Z., Mahaseth H., DeFor T.E., Weisdorf D.J. Bronchiolitis obliterans in chronic graft-versus-host disease: analysis of risk factors and treatment outcomes. Biol Blood Marrow Transplant 2003, 9:657-666.
12. Al-Githmi I., Batawil N., Shigemura N., et al. Bronchiolitis obliterans following lung transplantation. Eur J Cardiothorac Surg 2006, 30:846-851.
13. Chien J.W., Duncan S., Williams K.M., Pavletic S.Z. Bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplantation-an increasingly recognized manifestation of chronic graft-versus-host disease. Biol Blood Marrow Transplant 2010, 16(Suppl):S106-S114.
14. Browning J.L. B cells move to centre stage: novel opportunities for autoimmune disease treatment. Nat Rev Drug Discov 2006, 5:564-576.
15. Ratanatharathorn V., Ayash L., Reynolds C., et al. Treatment of chronic graft-versus-host disease with anti-CD20 chimeric monoclonal antibody. Biol Blood Marrow Transplant 2003, 9:505-511.
16. Cutler C., Miklos D., Kim H.T., et al. Rituximab for steroid-refractory chronic graft-versus-host disease. Blood 2006, 108:756-762.
17. Canninga-van Dijk M.R., van der Straaten H.M., Fijnheer R., et al. Anti-CD20 monoclonal antibody treatment in 6 patients with therapy-refractory chronic graft-versus-host disease. Blood 2004, 104:2603-2606.
18. Miklos D.B., Kim H.T., Miller K.H., et al. Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission. Blood 2005, 105:2973-2978.
19. Kharfan-Dabaja M.A., Mhaskar A.R., Djulbegovic B., Cutler C., Mohty M., Kumar A. Efficacy of rituximab in the setting of steroid-refractory chronic graft-versus-host disease: a systematic review and meta-analysis. Biol Blood Marrow Transplant 2009, 15:1005-1013.
20. Pavletic S.Z., Martin P., Lee S.J., et al. Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group report. Biol Blood Marrow Transplant 2006, 12:252-266.
21. Arora M., Nagaraj S., Witte J., et al. New classification of chronic GVHD: added clarity from the consensus diagnoses. Bone Marrow Transplant 2009, 43:149-153.
22. Cho B.S., Min C.K., Eom K.S., et al. Feasibility of NIH consensus criteria for chronic graft-versus-host disease. Leukemia 2009, 23:78-84.
23. Kim D.Y., Lee J.H., Lee J.H., et al. Reevaluation of the National Institutes of Health criteria for classification and scoring of chronic GVHD. Bone Marrow Transplant 2010, 45:1174-1180.
24. Perez-Simon J.A., Encinas C., Silva F., et al. Prognostic factors of chronic graft-versus-host disease following allogeneic peripheral blood stem cell transplantation: the national institutes health scale plus the type of onset can predict survival rates and the duration of immunosuppressive therapy. Biol Blood Marrow Transplant 2008, 14:1163-1171.
25. Pidala J., Kim J., Anasetti C., et al. NIH Consensus chronic graft vs. host disease global severity is associated with overall survival and non-relapse mortality. Haematol 2011, 96:1678-1684.
26. Sato T., Ichinohe T., Kanda J., et al. Clinical significance of subcategory and severity of chronic graft-versus-host disease evaluated by National Institutes of Health consensus criteria. Int J Hematol 2011, 93:532-541.
27. Jagasia M., Giglia J., Chinratanalab W., et al. Incidence and outcome of chronic graft-versus-host disease using National Institutes of Health consensus criteria. Biol Blood Marrow Transplant 2007, 13:1207-1215.
28. Lee S., Cook E.F., Soiffer R., Antin J.H. Development and validation of a scale to measure symptoms of chronic graft-versus-host disease. Biol Blood Marrow Transplant 2002, 8:444-452.
29. Pidala J., Kurland B., Chai X., et al. Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the Chronic GVHD Consortium. Blood 2011, 117:4651-4657.